| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
14-Hydroxy sprengerinin C targets as-yet-uncharacterized pathways. As a steroidal compound from Ophiopogon japonicus, it may interact with steroid hormone receptors or signaling pathways involved in inflammation, cardiovascular function, or other physiological processes. Specific molecular targets have not been definitively identified.
|
|---|---|
| ln Vitro |
In vitro activity data for 14-Hydroxy sprengerinin C are limited. As a steroidal saponin, it may exhibit a range of biological activities including anti-inflammatory, cardiovascular-protective, or immunomodulatory effects. Detailed in vitro assays and IC50 values have not been extensively reported.
|
| ln Vivo |
In vivo activity data for 14-Hydroxy sprengerinin C are limited. As a natural product from Ophiopogon japonicus, it may contribute to the traditional medicinal uses of this plant for cardiovascular health and other indications. Specific in vivo efficacy data are not available in the literature.
|
| Enzyme Assay |
In vitro receptor binding assays for 14-Hydroxy sprengerinin C are not extensively characterized. As a steroidal saponin, it could potentially interact with steroid hormone receptors, but specific binding studies have not been reported. Standard radioligand binding or SPR-based assays could be employed to identify potential targets.
|
| Cell Assay |
Cellular assays for 14-Hydroxy sprengerinin C are conducted using relevant cell lines to evaluate its biological activity. Cells are treated with the compound at concentrations ranging from 1-100 uM for 24-72 hours. Endpoints may include cell viability (MTT assay), inflammatory cytokine production (ELISA), or other functional readouts depending on the biological context.
|
| Animal Protocol |
In vivo animal studies for 14-Hydroxy sprengerinin C are not well-established in the literature. As a natural product, it could potentially be evaluated in animal models of inflammation, cardiovascular disease, or other conditions relevant to Ophiopogon japonicus. Specific protocols have not been reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 14-Hydroxy sprengerinin C are not extensively characterized. The compound has a molecular weight of 871.02 and formula C44H70O17. It is soluble in DMSO (10 mM) and other organic solvents. It is stored desiccated at -20degC. Bioavailability and half-life data are not available.
|
| Toxicity/Toxicokinetics |
Toxicological data for 14-Hydroxy sprengerinin C are limited. As a natural product from a medicinal plant, it is generally considered to have a moderate safety profile. Standard safety assessments would be required for therapeutic development. The compound is for research use only.
|
| Additional Infomation |
14-Hydroxy sprengerinin C (Saponin U) is a research-use natural product not approved for clinical therapeutic applications. It is a steroidal saponin isolated from Ophiopogon japonicus, a plant used in traditional Chinese medicine. The compound is used in natural product research to study the biological activities of steroidal saponins. It is for research use only and not for human therapeutic application.
|
| Molecular Formula |
C44H70O17
|
|---|---|
| Molecular Weight |
871.0164
|
| Exact Mass |
870.461
|
| CAS # |
1111088-89-1
|
| PubChem CID |
102004870
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.628
|
| LogP |
5.27
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
61
|
| Complexity |
1620
|
| Defined Atom Stereocenter Count |
25
|
| SMILES |
C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@]4([C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)O)C)OC1
|
| InChi Key |
AONBXCCYURJCAY-LSXBRKLISA-N
|
| InChi Code |
InChI=1S/C44H70O17/c1-19-8-13-44(55-17-19)20(2)29-27(61-44)15-43(53)25-7-6-22-14-23(9-11-41(22,4)24(25)10-12-42(29,43)5)57-40-37(60-39-34(51)32(49)30(47)21(3)56-39)35(52)36(28(16-45)58-40)59-38-33(50)31(48)26(46)18-54-38/h6,19-21,23-40,45-53H,7-18H2,1-5H3/t19-,20+,21+,23+,24+,25-,26-,27+,28-,29+,30+,31+,32-,33-,34-,35+,36-,37-,38+,39+,40-,41+,42-,43-,44-/m1/s1
|
| Chemical Name |
(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-4-hydroxy-6-(hydroxymethyl)-2-[(1R,2R,4S,5'R,6R,7S,8R,9R,12S,13R,16S)-2-hydroxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxy-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~114.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1481 mL | 5.7404 mL | 11.4808 mL | |
| 5 mM | 0.2296 mL | 1.1481 mL | 2.2962 mL | |
| 10 mM | 0.1148 mL | 0.5740 mL | 1.1481 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
